AR116713A1 - COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 - Google Patents
COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3Info
- Publication number
- AR116713A1 AR116713A1 ARP190102939A ARP190102939A AR116713A1 AR 116713 A1 AR116713 A1 AR 116713A1 AR P190102939 A ARP190102939 A AR P190102939A AR P190102939 A ARP190102939 A AR P190102939A AR 116713 A1 AR116713 A1 AR 116713A1
- Authority
- AR
- Argentina
- Prior art keywords
- imidazolindiona
- compounds
- channel regulators
- methyl
- attached
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de formula (1), en la que: R¹ es H o metilo; R² y R³ son ambos metilo, o R² y R³, junto con el átomo de carbono al que están unidos, son un anillo de espirociclopropilo; R⁴ es metilo o etilo; R⁵ es H o metilo; o R⁴ y R⁵, junto con el átomo de carbono al que están unidos, forman un espirocarbociclilo C₃₋₄; o una sal y/o solvato y/o derivado del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200626 | 2018-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116713A1 true AR116713A1 (es) | 2021-06-02 |
Family
ID=63878368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102939A AR116713A1 (es) | 2018-10-16 | 2019-10-16 | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3867247B1 (es) |
| JP (1) | JP7465868B2 (es) |
| KR (1) | KR20210076081A (es) |
| AR (1) | AR116713A1 (es) |
| AU (1) | AU2019360017A1 (es) |
| BR (1) | BR112021006940A2 (es) |
| DK (1) | DK3867247T3 (es) |
| IL (1) | IL282096B2 (es) |
| MX (1) | MX2021004386A (es) |
| TW (1) | TWI827706B (es) |
| WO (1) | WO2020079422A1 (es) |
| ZA (1) | ZA202101487B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009702A (es) * | 2020-02-06 | 2022-09-07 | Autifony Therapeutics Ltd | Moduladores de kv3. |
| AU2022328310A1 (en) | 2021-08-09 | 2024-03-28 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| CA3226856A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5788404B2 (ja) | 2009-12-11 | 2015-09-30 | アウトイフオンイ トヘラペウトイクス リミテッド | イミダゾリジンジオン誘導体 |
| CN103328467B (zh) * | 2010-12-06 | 2016-08-10 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| WO2012168710A1 (en) | 2011-06-07 | 2012-12-13 | Autifony Therapeutics Limited | Hydantoin derivates as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| MX356813B (es) | 2011-12-06 | 2018-06-13 | Autifony Therapeutics Ltd | Derivados de hidantoina utiles como inhibidores de kv3. |
| BR112014028991A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
| JP2015517563A (ja) | 2012-05-22 | 2015-06-22 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３阻害剤としてのヒダントイン誘導体 |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) * | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
-
2019
- 2019-10-16 MX MX2021004386A patent/MX2021004386A/es unknown
- 2019-10-16 AR ARP190102939A patent/AR116713A1/es unknown
- 2019-10-16 AU AU2019360017A patent/AU2019360017A1/en active Pending
- 2019-10-16 WO PCT/GB2019/052937 patent/WO2020079422A1/en active Application Filing
- 2019-10-16 JP JP2021521058A patent/JP7465868B2/ja active Active
- 2019-10-16 IL IL282096A patent/IL282096B2/en unknown
- 2019-10-16 DK DK19790048.3T patent/DK3867247T3/da active
- 2019-10-16 KR KR1020217014348A patent/KR20210076081A/ko active Search and Examination
- 2019-10-16 BR BR112021006940-2A patent/BR112021006940A2/pt unknown
- 2019-10-16 TW TW108137290A patent/TWI827706B/zh active
- 2019-10-16 EP EP19790048.3A patent/EP3867247B1/en active Active
-
2021
- 2021-03-04 ZA ZA2021/01487A patent/ZA202101487B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202101487B (en) | 2024-05-30 |
| JP2022505143A (ja) | 2022-01-14 |
| TWI827706B (zh) | 2024-01-01 |
| TW202035394A (zh) | 2020-10-01 |
| IL282096A (en) | 2021-05-31 |
| JP7465868B2 (ja) | 2024-04-11 |
| EP3867247A1 (en) | 2021-08-25 |
| KR20210076081A (ko) | 2021-06-23 |
| MX2021004386A (es) | 2021-06-04 |
| BR112021006940A2 (pt) | 2021-07-13 |
| IL282096B2 (en) | 2024-07-01 |
| EP3867247B1 (en) | 2024-07-24 |
| DK3867247T3 (da) | 2024-09-16 |
| WO2020079422A1 (en) | 2020-04-23 |
| AU2019360017A1 (en) | 2021-04-01 |
| IL282096B1 (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116713A1 (es) | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 | |
| TWD215802S (zh) | 鼻管組合 | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| AR113688A1 (es) | Proceso para la preparación de compuestos de piridiminio ópticamente activo | |
| BR112017006253A2 (pt) | novos compostos | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| MA52948B1 (fr) | Composés | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
| AR095721A1 (es) | Derivados de piridina | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR100439A1 (es) | Derivados de carboxamida | |
| AR084172A1 (es) | Derivados aminotriazol hidroxilados como agonistas del receptor alx | |
| AR084173A1 (es) | Derivados oxazolil-metileter como agonistas del receptor alx | |
| AR102539A1 (es) | Triazolo[4,5-d]pirimidinas | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
| CR20160562A (es) | Péptidos como agonistas de la oxitocina | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |